 understand busi schedul daili delug email monthli recap gena-edit compil note key topic
discuss ith client past month easi track also includ proprietari ork believ still
relev current topic
topic discuss client past month
impact trial enrol revenu gena-typ eek ith compani start
report neg impact investor larg expect eak revenu expect miss
compani investor expect suspens trial initi clinic trial delay on-going clinic trial
current market sentiment gena-typ eek base chines market recov recent day
investor ere optimist start look strateg select basket stock focus fundament cash
runw ay major investor ever remain concern macro environ expect declin given state-
gild remdesivir read-through gena-typ eek major investor expect gild
cover carter gould remdesivir trial posit drug approv could allevi market panic even though remdesivir like
 ould prevent spread viru hile posit remdesivir trial ere consid neg consid
remdesivir formul half-lif sub-optimal view ed opportun drug candid includ vir
impact stock gena-typ eek given increasingli critic situat
us investor continu cautiou overal market expect declin hile believ invest stock
 ith on-going drug develop could provid near-term upsid investor consid stock fair valu
initi feedback gena-typ eek investor consid current valuat alreadi fulli
reflect cf franchis valu saw pipelin asset earli provid meaning upsid investor believ
upsid faster launch uptak trikafta consid rel cheap hen compar ep grow th potenti vs
industri proprietari research note
updat gene therapi gene edit overview
feedback kol call replay transcript kol call
implic coverag univers
takeaw ay retin kol call
feedback barclay global healthcar confer
alny/vir deal provid addit modal treat
gena-chart eek
gena-chart eek
gena-typ eek
gena-typ eek
gena-typ eek
gena-typ eek
 increment eye updat
 zolgensma posit chmp opinion expect
 highlight oppt eye trial initi
 updat impact
 updat continu demonstr benefit sma type pre-symptomat
 provid detail ind hold eye clinic updat
 unev eye initi enrol pivot studi
idra unev eye clinic updat
 increment eye clinic updat
 unev eye addit data granit slate
 unev eye allo-car-t addit data
 unveil plan pipelin updat track
cll studi on-track evalu
 initi coverag overw eight
 increment eye firefish translarna biomark data
zyme unev eye zw initi data
 beam ith potenti initi ow
updat gene therapi gene edit overview
genfit inc deep dive elafibranor nash reiter ow
us smid cap biotech takeaw ay etamd kol call post-angiogenesi replay transcript etamd
kol call post-angiogenesi
us smid cap biotech sunfish part takeaw ay investor call kol feedback favor replay transcript
kol call post-sma europ
zymew ork inc deep dive zw adc
biomarin deep dive vosoritid
us smid cap biotech takeaw ay et kol call post-aao replay transcript kol
 takeaw ay kol confer call protein quantif dmd gene therapi replay transcript
kol confer call protein quantif dmd gene therapi
 takeaw ay kol confer call muscular dystrophi replay transcript kol confer call
muscular dystrophi
 takeaw ay sma kol discuss post replay transcript post- kol
discuss sma
us smid cap biotech asgct kol dinner gene therapi
mirati inc deep dive kra inhibitor anoth drug class horizon
us smid cap biotech deep dive dmd gene therapi
confer call transcript replay payer discuss gene/cel therapi reimburs
takeaw ay kol reimburs gene cell therapi
initi stock ith industri overview initi ith posit view
let us know question
gena peter david
gena ang phd cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog pt base sum-of-the-part probability-adjust dcf includ bt/scd
aml/al ell technolog platform
 assign technolog platform hile acknow ledg exact valuat technolog subject believ
base edit platform repres differenti substanti market opportun futur therapi assign
termin valu clinic asset use discount rate reflect commerci risk hich believ appropri given
risk may imped achiev barclay research valuat price clinic risk
result preclin studi and/or early-stag studi serv basi proof-of-concept efficaci safeti
therapeut candid initi encourag result ith respect activ safeti might translat success later-
even therapeut candid met primari endpoint show ed clinic activ guarante approv ould issu
regulatori agenc review ing process regulatori agenc might take longer expect regulatori agenc
might request addit trial conduct actual approv
drug launch might success due oper ineffici and/or competit despit regulatori approv agreement
compani ith partner might chang time hich could materi impact develop and/or commerci
drug candid market exclus render patent protection/extens statutori provis might end earlier
expect hich might impact drug sale price pow er innov drug might affect substanti chang current
addit cash might need support develop clinic program reach profit
rate price target histori
histor stock price price target may adjust stock split dividend
valuat methodolog price target gnft base sum-of-the-part probability-adjust discount cash flow
dcf includ elafibranor nash elafibranor pbc assign termin valu clinic asset
use discount rate reflect commerci risk hich believ appropri given probability-adjust revenu
risk may imped achiev barclay research valuat price upsid risk rate
price target includ faster expect clinic progress ith posit result better anticip sale key product
candid current includ elafibranor monotherapi nash pbc forecast potenti upsid pipelin
asset includ estimates/valu includ indic present valuat neg develop
part potenti competitor clinic trial failur emerg advers event result restrict label diminish
use rival product better cash conserv earlier achiev profit acquisit potenti larger biopharma
look immunolog asset
nside risk rate price target includ pipelin clinic trial failur setback includ emerg materi
advers event lead pipelin product potenti need addit capit rais fund clinic develop oper
dilut risk convert share equiti issuanc emerg new therapi render current commerci stage pipelin
product obsolet make less clinic commerci relev potenti price pressur upon success approv
due competit payor pushback
rate price target histori
histor stock price price target may adjust stock split dividend
valuat methodolog valuat base probability-adjust dcf current asset includ kalydeco
orkambi symdeko trikafta aatd assign
technolog platform hile acknow ledg exact valuat technolog subject believ
addit valu technolog platform justifi given demonstr capabl assign termin valu
clinic asset use discount rate hich believ appropri reflect risk asset
risk may imped achiev barclay research valuat price clinic risk
result preclin studi and/or early-stag studi serv basi proof-of-concept efficaci safeti
therapeut candid initi encourag result ith respect activ safeti might translat success later-
even therapeut candid met primari endpoint show ed clinic activ guarante approv ould issu
regulatori agenc review ing process regulatori agenc might take longer expect regulatori agenc
might request addit trial conduct actual approv
drug launch might success due oper ineffici and/or competit despit regulatori approv agreement
compani ith partner might chang time hich could materi impact develop and/or commerci
drug candid market exclus render patent protection/extens statutori provis might end earlier
expect hich might impact drug sale price pow er innov drug might affect substanti chang current
addit cash might need support develop clinic program reach profit
rate price target histori
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
unless otherw ise indic price sourc bloomberg reflect close price relev trade market hich
may last avail price time public
